Oncology Central

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?


Epigenetic changes, similar to mutations, have been implicated in the malignant behavior of tumors. Although the rate of acquisition of somatic mutations plateaus early in mammalian life, epigenetic drift of the genome steadily increases with age [1,2]. DNA methylation of CpG sites in gene promoters is a physiologic process in silencing genes important for development. This process is usurped in cancer and stable aberrant methylation maintaining reduced expression of genes in malignant cells is essential to their success.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.